

Objection removed according to the 1st reviewer

1. To see the response in different age groups with different drug combinations patients of both groups were divided in two age categories by 40 years. The results shows that relapse rate of the patients with more than 40 years was high that was also mentioned by the reviewer in paragraph no 2.
2. High relapse rate of the patients with more than 40 years in second group may be due to intolerance of peg-IFN in old age patients that was also mentioned in previous studies (ref 31-33). The reason is clearly mentioned in paragraph 5 of discussion section.
3. Ribavirin was adjusted according the patient's body weight (1000-1200mg/day) as mentioned in paragraph 3 of Materials and methods section.
4. Drugs used in this study were FDA approved and commonly used worldwide to treat the Hepatitis C patients. Secondly, in Pakistan there is no routine of drug registration as mentioned in drug registration statement.

Objection removed according to the 2nd reviewer

1. **Running title modified as:** Response of Sofosbuvir in Pakistani HCV patients.
2. Result section of abstract has been described most precisely.
3. Latest references added in the introduction (Ref. 20-22).
4. Ok
5. Ok
6. Latest references including Wahid et al., 2017 and Azam et., 2017 are added (ref. 21&22)

Objection removed according to the 3rd reviewer

Response rate to Sofosbuvir in hepatitis C patients infected with genotype 3 has been reported 90-99% previously from Pakistan. This drug was also well tolerated by the patients (Ref. 20-22).

The recommendations for the treatment of hepatitis C especially HCV genotype 3 with Sofosbuvir are given below

European Association for the Study of the Liver. EASL recommendations on treatment of Hepatitis C 2014. *J Hepatol* 2014; **61**: 373-395 [PMID: 24818984 DOI: 10.1016/j.jhep.2014.05.001]

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of Hepatitis C virus infection. *J Hepatol* 2014; **60**: 392-420 [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003]

WHO and PMRC guidelines for Hepatitis C 2016 available on <https://www.dropbox.com/s/u8bv7196scohsh7/HCV%20Treatment%20Guidelines.pdf?dl=0>

Sovaldi Prescribing information (updated on Apr- 2017) available on http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf